FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893566820> ?p ?o ?g. }

• W2893566820 endingPage "AB004" @default.
• W2893566820 startingPage "AB004" @default.
• W2893566820 abstract ": Global prostate cancer epidemiology has evolved in recent years, reflecting complex shifts in life expectancy, diet and lifestyle, and screening practices. Experience in the US over the past 20 years has clearly demonstrated that implementation of early prostate cancer detection through ad hoc prostate specific antigen (PSA) testing mostly of older men will lead to substantial rates of overdiagnosis, and potentially to avoidable harms of overtreatment—yet is largely responsible for a >50% reduction in age-adjust prostate cancer mortality rates. The recommendation of the US Preventive Services Task Force in 2012 that no men should be screened for prostate cancer has driven down both diagnosis of low-risk disease (less overdiagnosis) and high-risk disease (more under-diagnosis), and rates of metastatic disease at diagnosis are now rising. Emerging research suggests strongly that neither a “screen all” nor “screen none” approach is optimal—but rather than a smarter screening paradigm can further affect mortality reductions while simultaneously minimizing overtreatment. The best evidence from randomized trials suggests that relative prostate cancer mortality can be reduced by ~30–50% through screening, and most contemporary guidelines recommend shared decision making for men in their 50s to 60s, though there is disagreement regarding optimal starting age, and none of the guidelines comments on how to screen. Excellent cohort studies suggest that early (age 45–55) baseline testing, with subsequent intervals driven by baseline findings, may be optimal. PSA should not be interpreted in a vacuum, but rather considered in light of age, family history, race, physical exam findings, and other parameters, and calculators are available to facilitate such a multivariable assessment. Moreover, a growing array of secondary tests are available to help men with mildly elevated PSAs make decisions about biopsy—these include blood tests (4K, phi), urine tests (e.g., PCA3, MiPS, SelectMDx), and imaging tests (multiparametric MRI), each with strengths and limitations. At time of diagnosis, prostate cancers should be risk stratified, ideally using a multivariable instrument rather than a risk grouping system. A growing consensus supports active surveillance as the preferred strategy for most men with low grade (Gleason grade group 1) disease, and even for carefully selected men with grade group 2 tumors. These decisions may be further tailored with MRI and/or tissue-based biomarkers assessing gene expression patterns. Tailored approaches to screening and management—with deintensification of surveillance strategies for men with low risk disease, and intensified, multimodal approaches for those with high-risk disease—should allow both further gains in prostate cancer mortality reduction and minimization of the impact of avoidable overdiagnosis and overtreatment." @default.
• W2893566820 created "2018-10-05" @default.
• W2893566820 creator A5086007942 @default.
• W2893566820 date "2018-09-01" @default.
• W2893566820 modified "2023-10-18" @default.
• W2893566820 title "AB004. Rational and risk-stratified prostate cancer screening and treatment" @default.
• W2893566820 doi "https://doi.org/10.21037/tau.2018.ab004" @default.
• W2893566820 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6186751" @default.
• W2893566820 hasPublicationYear "2018" @default.
• W2893566820 type Work @default.
• W2893566820 sameAs 2893566820 @default.
• W2893566820 citedByCount "0" @default.
• W2893566820 crossrefType "journal-article" @default.
• W2893566820 hasAuthorship W2893566820A5086007942 @default.
• W2893566820 hasBestOaLocation W28935668201 @default.
• W2893566820 hasConcept C121608353 @default.
• W2893566820 hasConcept C126322002 @default.
• W2893566820 hasConcept C133925201 @default.
• W2893566820 hasConcept C177713679 @default.
• W2893566820 hasConcept C2775941076 @default.
• W2893566820 hasConcept C2779134260 @default.
• W2893566820 hasConcept C2779377019 @default.
• W2893566820 hasConcept C2780192828 @default.
• W2893566820 hasConcept C2781179581 @default.
• W2893566820 hasConcept C2781406297 @default.
• W2893566820 hasConcept C2908647359 @default.
• W2893566820 hasConcept C29456083 @default.
• W2893566820 hasConcept C71924100 @default.
• W2893566820 hasConcept C72563966 @default.
• W2893566820 hasConcept C99454951 @default.
• W2893566820 hasConceptScore W2893566820C121608353 @default.
• W2893566820 hasConceptScore W2893566820C126322002 @default.
• W2893566820 hasConceptScore W2893566820C133925201 @default.
• W2893566820 hasConceptScore W2893566820C177713679 @default.
• W2893566820 hasConceptScore W2893566820C2775941076 @default.
• W2893566820 hasConceptScore W2893566820C2779134260 @default.
• W2893566820 hasConceptScore W2893566820C2779377019 @default.
• W2893566820 hasConceptScore W2893566820C2780192828 @default.
• W2893566820 hasConceptScore W2893566820C2781179581 @default.
• W2893566820 hasConceptScore W2893566820C2781406297 @default.
• W2893566820 hasConceptScore W2893566820C2908647359 @default.
• W2893566820 hasConceptScore W2893566820C29456083 @default.
• W2893566820 hasConceptScore W2893566820C71924100 @default.
• W2893566820 hasConceptScore W2893566820C72563966 @default.
• W2893566820 hasConceptScore W2893566820C99454951 @default.
• W2893566820 hasIssue "S5" @default.
• W2893566820 hasLocation W28935668201 @default.
• W2893566820 hasLocation W28935668202 @default.
• W2893566820 hasLocation W28935668203 @default.
• W2893566820 hasOpenAccess W2893566820 @default.
• W2893566820 hasPrimaryLocation W28935668201 @default.
• W2893566820 hasRelatedWork W103670294 @default.
• W2893566820 hasRelatedWork W2057960756 @default.
• W2893566820 hasRelatedWork W2109046819 @default.
• W2893566820 hasRelatedWork W2171626530 @default.
• W2893566820 hasRelatedWork W2526330449 @default.
• W2893566820 hasRelatedWork W2784293637 @default.
• W2893566820 hasRelatedWork W2885626395 @default.
• W2893566820 hasRelatedWork W2966258052 @default.
• W2893566820 hasRelatedWork W4242730600 @default.
• W2893566820 hasRelatedWork W4280590802 @default.
• W2893566820 hasVolume "7" @default.
• W2893566820 isParatext "false" @default.
• W2893566820 isRetracted "false" @default.
• W2893566820 magId "2893566820" @default.
• W2893566820 workType "article" @default.